drugset / Trial / NCT04551261

GLS4/RTV and TAF Drug-drug Interaction

NCT04551261 ↗

Phase 1 Completed 28 enrolled Sunshine Lake Pharma Co., Ltd.
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of GLS4/RTV combined with TAF in healthy subjects.

Timeline

Start
2021-01-10
Primary completion
2021-03-12
Completion
2021-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GLS4 Other / unclassified — —
Subject RTV Unknown — —
Subject TAF Unknown — —